London pre-open: Stocks seen lower ahead of busy week
London stocks were set to fall at the open on Monday following a mostly weaker Asian session. The FTSE 100 was called to open ...
Pharmabiz2h
EMA validates X4 Pharma’s marketing authorization application for mavorixafor to treat WHIM syndrome
EMA validates X4 Pharma’s marketing authorization application for mavorixafor to treat WHIM syndrome: Boston Monday, January 27, 2025, 11:00 Hrs [IST] X4 Pharmaceuticals, a comp ...
WH Smith mulling sale of high street stores, Diversified buys Maverick Natural Resources
London open The FTSE 100 is expected to open 51 points lower on Monday, having closed down 0.73% on Friday at 8,502.35.
FDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease
Once every four weeks maintenance dosing may be easier for patients and care partners to continue treatmentAlzheimer's disease progression does ...
BioArctic: FDA approves IV maintenance dosing of Leqembi (lecanemab-irmb) for the treatment of early Alzheimer's Disease in the US
BioArctic AB (publ) (NASDAQ STOCKHOLM: BIOA B) today announced that the U.S. Food and Drug Administration (FDA) has approved BioArctic's partner Eisai's ...
finanzen6h
FDA Approves Once-Every-Four-Weeks Maintenance Dosing Of LEQEMBI For Early Alzheimer's Disease
Eisai Co., Ltd. (ESALF.PK) and Biogen Inc. (BIIB) announced Sunday that the U.S. Food and Drug Administration has approved the ...
Irish Independent on MSN7h
Wicklow mother calls for access to life-saving therapy for son with rare form of Cystic Fibrosis
A Wicklow mother is among a concerned group of parents who are calling for individual trials of the modulator therapies for their children with Cystic Fibrosis who still do not have access to these ...
Buy21m
LONDON BRIEFING: Diageo rules out Guinness sale; Dr Martens backs view
Colombia on Sunday backed down and agreed to accept deported citizens sent on US military aircraft, hours after President Trump threatened painful tariffs to punish the defiance to his mass ...
Le Lézard3h
CStone Partners with SteinCares to Market Sugemalimab in Latin America
CStone will receive upfront, regulatory and commercial milestone payments, and book revenue from SteinCares through the supply of sugemalimab in 10 Latin American (LATAM) countries. This ...
FDA approves IV maintenance dosing of Leqembi® (lecanemab-irmb) for the treatment of early Alzheimer's Disease in the US
BioArctic AB (publ) (NASDAQ STOCKHOLM: BIOA B) today announced that the U.S. Food and Drug Administration (FDA) has approved BioArctic's partner Eisai's Supplemental Biologics License Application ...
US FDA OKs monthly maintenance dosing for Eisai/Biogen's Alzheimer's drug
The U.S. Food and Drug Administration has approved monthly maintenance dosing for Japan's Eisai and partner Biogen's ...